News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,752 Results
Type
Article (43718)
Company Profile (473)
Press Release (694549)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209328)
Career Advice (2041)
Deals (36152)
Drug Delivery (119)
Drug Development (83976)
Employer Resources (174)
FDA (16700)
Job Trends (15193)
News (354192)
Policy (33289)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2659)
Accelerated approval (37)
Adcomms (28)
Allergies (147)
Alliances (51111)
ALS (179)
Alzheimer's disease (1737)
Antibody-drug conjugate (ADC) (335)
Approvals (16942)
Artificial intelligence (552)
Autoimmune disease (166)
Automation (41)
Bankruptcy (373)
Best Places to Work (11842)
BIOSECURE Act (20)
Biosimilars (196)
Biotechnology (331)
Bladder cancer (163)
Brain cancer (61)
Breast cancer (656)
Cancer (4983)
Cardiovascular disease (424)
Career advice (1726)
Career pathing (38)
CAR-T (295)
CDC (47)
Celiac Disease (2)
Cell therapy (789)
Cervical cancer (36)
Clinical research (71502)
Collaboration (1818)
Company closure (4)
Compensation (1195)
Complete response letters (67)
COVID-19 (2775)
CRISPR (102)
C-suite (904)
Cystic fibrosis (152)
Data (6381)
Decentralized trials (2)
Denatured (39)
Depression (145)
Diabetes (507)
Diagnostics (6767)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (272)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (247)
Earnings (91529)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121133)
Executive appointments (1015)
FDA (19886)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1548)
Gene editing (218)
Generative AI (45)
Gene therapy (651)
GLP-1 (1012)
Government (4765)
Grass and pollen (6)
Guidances (385)
Healthcare (19214)
HIV (64)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (280)
Immuno-oncology (63)
Indications (117)
Infectious disease (3056)
Inflammatory bowel disease (202)
Inflation Reduction Act (17)
Influenza (122)
Intellectual property (259)
Interviews (316)
IPO (16933)
IRA (53)
Job creations (3714)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8034)
Liver cancer (93)
Longevity (14)
Lung cancer (674)
Lymphoma (385)
Machine learning (43)
Management (59)
Manufacturing (827)
MASH (172)
Medical device (13929)
Medtech (13984)
Mergers & acquisitions (20306)
Metabolic disorders (1328)
Multiple sclerosis (168)
NASH (19)
Neurodegenerative disease (346)
Neuropsychiatric disorders (97)
Neuroscience (3046)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4587)
Now hiring (68)
Obesity (637)
Opinion (286)
Ovarian cancer (169)
Pain (205)
Pancreatic cancer (236)
Parkinson's disease (298)
Partnered (34)
Patents (511)
Patient recruitment (511)
Peanut (57)
People (60360)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22488)
Phase 2 (31525)
Phase 3 (23303)
Pipeline (5486)
Policy (301)
Postmarket research (2602)
Preclinical (9613)
Press Release (67)
Prostate cancer (247)
Psychedelics (56)
Radiopharmaceuticals (303)
Rare diseases (907)
Real estate (6065)
Recruiting (71)
Regulatory (25065)
Reports (53)
Research institute (2490)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (80)
Schizophrenia (156)
Series A (257)
Series B (203)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1043)
Venture capital (96)
Weight loss (411)
Women's health (94)
Worklife (19)
Date
Today (154)
Last 7 days (598)
Last 30 days (2400)
Last 365 days (30797)
2026 (3964)
2025 (31063)
2024 (36298)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54922)
2019 (47418)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38397)
2014 (32185)
2013 (27109)
2012 (29222)
2011 (29864)
2010 (27994)
Location
Africa (754)
Alabama (90)
Alaska (7)
Arizona (319)
Arkansas (14)
Asia (40720)
Australia (6767)
California (11594)
Canada (3334)
China (1147)
Colorado (489)
Connecticut (503)
Delaware (342)
Europe (89311)
Florida (1716)
Georgia (363)
Hawaii (3)
Idaho (61)
Illinois (894)
India (69)
Indiana (530)
Iowa (24)
Japan (442)
Kansas (131)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1417)
Massachusetts (8421)
Michigan (330)
Minnesota (643)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3083)
New Mexico (31)
New York (3041)
North Carolina (1550)
North Dakota (9)
Northern California (5648)
Ohio (340)
Oklahoma (21)
Oregon (45)
Pennsylvania (2326)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4500)
Tennessee (178)
Texas (1781)
United States (41247)
Utah (343)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (962)
West Virginia (4)
Wisconsin (116)
Wyoming (2)
738,752 Results for "amicus therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
February 3, 2026
·
10 min read
Press Releases
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
November 5, 2025
·
18 min read
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
Press Releases
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
October 31, 2025
·
1 min read
Press Releases
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
December 22, 2025
·
23 min read
Press Releases
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
October 23, 2025
·
1 min read
Press Releases
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
August 29, 2025
·
1 min read
Press Releases
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
July 31, 2025
·
18 min read
Press Releases
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
June 25, 2025
·
4 min read
1 of 73,876
Next
